Ohio State University Ranks 28th in 2024 Cure Innovation Index, Showcasing Strength in Biomedical Research and Commercialization

Columbus, OH — May 20, 2026 — The Ohio State University has solidified its position as a national leader in biomedical innovation, earning a Top 30 ranking (28th nationally) in the Cure Innovation Index, a benchmark measuring universities’ ability to advance medical breakthroughs from lab to patient. The ranking, released in 2024, highlights Ohio State’s balanced strengths across research capabilities, market translation, and entrepreneurial readiness, positioning it as a key player in accelerating cures for diseases.

Why the Ranking Matters: Ohio State’s Three Pillars of Innovation

The Cure Innovation Index evaluates institutions based on three core domains. Ohio State’s performance reveals a university with a well-integrated biomedical enterprise, though with room for growth in faculty-driven commercialization. Here’s how it stacks up:

• Research Capabilities (Top 30 nationally): Ohio State excels in the foundational infrastructure needed for groundbreaking science. Its strengths include:
  • Funding Support: The university secures substantial grants and partnerships to fuel high-impact research.
  • Cutting-Edge Science: Faculty and researchers contribute to advancements in areas like cancer, neuroscience, and infectious diseases.
  • Facilities/Equipment: State-of-the-art labs and clinical trial infrastructure support translational work.
• Market Translation (Top 30 nationally): Ohio State effectively bridges the gap between discovery and real-world impact. Key assets include:
  • A Clinical and Translational Science Award (CTSA), which funds collaborative research projects.
  • Active faculty-led clinical trials, including partnerships with the Ohio State Wexner Medical Center.
  • Programs like the Medical Scientist Training Program (MSTP), which trains the next generation of physician-scientists.
• Entrepreneurial Readiness (Below Average): While Ohio State provides robust ecosystem support—such as incubators and biomedical entrepreneurship training—it ranks below average in faculty engagement and commercialization incentives. This suggests an opportunity to further incentivize spin-out companies and startup formation.

What the Ranking Reveals About Ohio’s Biomedical Ecosystem

Ohio State’s ranking reflects broader trends in the state’s innovation landscape. With Columbus as its hub, Ohio is home to a growing cluster of research institutions, biotech startups, and corporate partnerships. The university’s performance underscores:

• Strong Public-Private Collaboration: Ohio State partners with organizations like the Ohio Department of Higher Education and local biotech firms to accelerate commercialization.
• Investment in Workforce Development: Programs like the MD/MBA dual degree prepare students to lead both research and business ventures.
• National Competition: While Ohio State ranks outside the Top 10, its consistent performance across all three domains places it ahead of many peer institutions in translating research into tangible health outcomes.

Key Takeaways: How Ohio State Compares to Peers

To contextualize Ohio State’s ranking, here’s how it compares to other top institutions in the Cure Innovation Index:

Source: Cure Innovation Index 2024

FAQ: Ohio State’s Innovation Ranking Explained

1. What is the Cure Innovation Index?

The Cure Innovation Index is an annual benchmark developed by We Will Cure, a nonprofit focused on accelerating medical breakthroughs. It evaluates universities based on their ability to:

• Conduct high-quality research (Research Capabilities).
• Translate discoveries into clinical and commercial applications (Market Translation).
• Foster entrepreneurship and startup formation (Entrepreneurial Readiness).

2. Why does Ohio State rank lower in Entrepreneurial Readiness?

While Ohio State provides strong infrastructure—such as incubators and funding for early-stage ventures—its ranking in this category suggests that fewer faculty members are actively engaged in commercializing their research compared to top-ranked institutions. The university may need to incentivize spin-outs or improve pathways for researchers to transition ideas into businesses.

3. How does Ohio State’s ranking impact students and researchers?

Ohio State’s Top 30 ranking enhances its reputation as a destination for students and researchers seeking:

• Cutting-edge research opportunities in biomedical fields.
• Access to clinical trials and translational programs, such as the MSTP.
• Networking with industry partners, including biotech and pharmaceutical companies.

4. What’s next for Ohio State in innovation?

To climb higher in future rankings, Ohio State may focus on:

• Increasing faculty incentives for commercialization, such as equity in spin-out companies.
• Strengthening partnerships with venture capital firms to fund early-stage biotech startups.
• Expanding industry collaborations to streamline the translation of research into products.

Looking Ahead: Ohio’s Role in the Future of Biomedical Innovation

Ohio State’s consistent performance in the Cure Innovation Index signals its growing influence in the biomedical sector. As the university continues to invest in translational research and entrepreneurship, it has the potential to move up the rankings—and contribute even more to life-saving discoveries. For now, its balanced approach across research, clinical application, and ecosystem support makes it a standout institution in the Midwest and a competitive player on the national stage.

For more on Ohio State’s innovation initiatives, visit the Office of Research or explore the full Cure Innovation Index rankings here.